Put It on the Board

Create PDF

Werfen CEO Carlos Pascual called the acquisition a “major milestone” in Werfen’s future and said, “Immucor’s expertise and innovations in transfusion and transplant diagnostics enable us to enter new markets and will help achieve our vision to be the preferred choice of the most advanced laboratory and point-of-care customers, globally.”

The transaction is expected to close during the first half of 2023.

Illumina introduces research panel for genitourinary pathogen ID

Illumina introduced a research test for genitourinary pathogen and antimicrobial resistance identification. The Illumina Urinary Pathogen Infectious Disease/Antimicrobial Resistance Panel (UPIP) applies precision metagenomics to detect and quantify pathogens, including those that are drug resistant.

In less than 48 hours, Illumina says, UPIP, a next-generation sequencing-based panel, detects and quantifies more than 170 organisms that can cause genitourinary infections and more than 3,700 antimicrobial resistance markers associated with 18 different drug classes. Combined with the use of Explify, a fully automated data analysis platform, this workflow provides a comprehensive infection profile across bacterial, fungal, viral, and parasitic microbes.

“The growing threat of infections by common and uncommon microbes with growing antimicrobial drug resistance is alarming; public health and private laboratories require new tools to fight emerging threats,” Phil Febbo, MD, chief medical officer of Illumina, said in a news release. The UPIP test, he said, is “a unique opportunity for microbiologists and clinical researchers to rapidly identify pathogens and potential drug resistance for complicated or recurrent urinary infections.”

Biocare Medical acquires Empire Genomics

Biocare Medical announced its acquisition of Empire Genomics, a designer, manufacturer, and distributor of a comprehensive menu of clinical and custom-labeled molecular probes.

“This acquisition complements our broad portfolio of IHC antibodies, robust molecular menu, and advanced automation platforms,” Biocare Medical CEO Luis de Luzuriaga said in a news release.